

Registered Office:

815, Nilamber Triumph, Vasna-Gotri Road, Vadodara - 390 012. Gujarat (INDIA).

Email: admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.pardrugs.com

PAR/CS/NSE/2021-22/21

Date: 10/06/2021

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Subject: Clarification with respect to an announcement submitted to the Exchange dated Jun 10,2021, regarding starting a new product line facility.

Ref.: Symbol- PAR (NSE Emerge), ISIN: INE04LG01015

Respected sir/ Madam,

As per your requirement, we hereby submit our clarification, regarding outcome of board meeting held on Thursday,  $10^{th}$  day of June, 2021 is as follows:

We have mentioned that it's starting of a new product line which means it is a set of new production line-up which increases production capacity within the existing product portfolio. It is an expansion of production capacity. We have never mentioned of launching of any new product.

Moreover, with connection to above explanation of your all queries having same collective answer which may be explained as "same as per our existing product portfolio and market".

Srn.	Particulars	Clarification
1.	Name of the product	No new product launched
2.	Date of launch	Not Applicable
3.	Category of the product	Not Applicable
4.	Whether caters to domestic/ international market	Not Applicable
5.	Name of the countries in which the product is	Not Applicable
	launched (in case of international).	, ,

We hope above clarification fits your requirements.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)

**Company Secretary & Compliance Officer** 

